Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAP-DEX study of dexamethasone for severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype
2023-508153-12-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) comparing Dexamethasone plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Clinical cure at test-of-cure visit and All-cause mortality at Day 28. Planned start Mar 2024; status: authorised.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2023-508153-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508153-12-00.